Podcasts about Weill Cornell Medicine

DAPT back in the news, a practice-changing trial in VTE therapy, new knowledge in sudden cardiac death, heart failure definitions updated, and a dumb decision by NICE in the UK are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Antiplatelet Therapy After Stenting DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588 HOST-EXAM Trial at 2 years https://pubmed.ncbi.nlm.nih.gov/34010616/ HOST-EXAM Trial at 10 years 10.1016/S0140-6736(26)00422-8 External Link Nick Kurzen on X https://x.com/ncurzen/status/2077676739463922151 II Aspirin Proves Its Mettle After Hip and Knee Replacement EPCAT III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2603649 CRISTAL Trial https://jamanetwork.com/journals/jama/fullarticle/2795528 III New (and old) Knowledge in Sudden Cardiac Death Sudden Cardiac Death and its Relation to Cardiac Disease at Autopsy https://doi.org/10.1016/j.jacc.2026.01.029 Sudden Cardiac Death Due to MI With Obstructive and Nonobstructive Coronary Arteries https://doi.org/10.1016/j.jacc.2026.01.030 Frequency of Sudden Cardiac Death and Profiles of Risk https://www.ajconline.org/article/S0002-9149(97)00477-3/fulltext IV Heart Failure Diagnosis AHA/ACC/ESC/WHF Expert Consensus Document http://jacc.org/doi/10.1016/j.jacc.2026.05.036 V NICE Makes a Dumb Decision NICE Recommends New Nonsteroidal MRA for Heart Failure https://www.medscape.com/viewarticle/nice-recommends-new-nonsteroidal-mra-heart-failure-2026a1000nzv You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Peptides are everywhere in the healthcare zeitgeist. On social media, you're likely to encounter an influencer claiming that injecting or ingesting peptides can improve your skin, build muscle,increase focus or help you lead a longer and healthier life. Peptides are short chains of amino acids that are fundamental building blocks in protein and our bodies make them naturally. While some synthetic peptides like insulin and GLP-1s are widely used and approved, the off market use of other peptides have raised concerns among scientists. We'll talk about the promise, dangers and hype of peptides. Dhruv Khullar, physician at Weill Cornell Medicine; associate professor at Weill Cornell Medical College; contributing writer, The New Yorker Zara Stone, tech culture reporter, The San Francisco Standard Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailWe usually think of health ministers as politicians. Dr. Evis Sala, MD, PhD is something entirely different. She's one of the world's leading cancer imaging researchers who helped pioneer AI in radiology - and now she's responsible for the healthcare of an entire nation. What happens when a scientist takes the helm of public health?Our guest today is one of the world's leading physician-scientists in medical imaging who has recently taken on one of the biggest leadership challenges in healthcare.Dr. Evis Sala, MD, PhD ( https://www.kryeministria.al/en/ministrat/evis-sala/ ) currently serves as the Minister of Health and Social Protection of Albania  ( https://shendetesia.gov.al/en/hap/ ). Before entering government, Dr. Sala built an extraordinary international career spanning the University of Cambridge, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and Rome's Policlinico Gemelli, while becoming internationally recognized for her pioneering work in advanced cancer imaging, precision diagnostics, women's cancers, and the integration of artificial intelligence into radiology.Holding both an MD from the University of Tirana and a PhD in Epidemiology from the University of Cambridge, Dr. Sala has spent decades helping shape how we detect, diagnose, and ultimately treat cancer. Today, she is applying that scientific rigor and international experience to improving the health of an entire nation.#EvisSala #Healthcare #PublicHealth #Medicine #ArtificialIntelligence #AI #Radiology #CancerResearch #PrecisionMedicine #CancerImaging #MedicalInnovation #DigitalHealth #HealthPolicy #Oncology #MRI #FutureOfMedicine #HealthcareInnovation #MedicalTechnology #SciencePodcast #ProgressPotentialPossibilitiesSupport the show

Listener feedback on ICE vs TEE in AF ablation, fractional flow reserve without a wire or catheter, more bad news for ticagrelor, the POLY-HF trial, and oxygen targets after cardiac arrest are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Oct 10, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002990 ICE vs TEE in Atrial Fibrillation Ablation https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 II FFR Without the Wire – Angiography-Derived FFR to Guide PCI ALL-RISE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600949 FAST III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601841 FAVOR III Trial 10.1016/S0140-6736(24)02175-5 External Link FAME 2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1205361   Venk Murthy on X https://x.com/venkmurthy/status/2074849421452329456?s=20 III More Bad News for Ticagrelor Jul 11, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002704 Prasugel, Ticagrelor, or Clopidogrel After PCI https://jamanetwork.com/journals/jamacardiology/fullarticle/2849614 IV The Polypill in Heart Failure POLY-HF trial https://www.nature.com/articles/s41591-026-04504-5 V Oxygen Targets After Cardiac Arrest LOGICAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513814 ICU-ROX Trial https://link.springer.com/article/10.1007/s00134-020-06196-y Secondary Analysis of the PILOT Trial https://journal.chestnet.org/article/S0012-3692(25)00553-7/fulltext Oxygen Targets in Comatose Survivors of Cardiac Arrest https://www.nejm.org/doi/10.1056/NEJMoa2208686 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Being told you're "the glue that keeps everything together" sounds like a compliment—until you realize it's the very reason they never considered you for the promotion. Dr. Ruth Gotian spent 15 years being perfect at her job, and it almost cost her everything. Dr. Ruth Gotian is the Chief Learning Officer at Weill Cornell Medicine (recently retired), a Columbia University faculty member, and one of the world's foremost researchers on peak performance. She has interviewed Nobel Prize winners, Olympians, NASA astronauts, and NBA champions—not to report on their habits, but to decode the mindset patterns behind their greatness. Her book The Success Factor has become a roadmap for high achievers who are tired of being overlooked. In this episode, Kwame and Ruth unpack the hidden rules of success that nobody tells you—and what it actually takes to go from invisible to undeniable. Connect with Dr. Ruth Gotian: Website: ruthgotian.com LinkedIn: Search Ruth Gotian The Success Factor — featuring stories from Neil Katyal, Steve Kerr, Bob Lefkowitz, and Peggy Whitson Upcoming book on overlooked high achievers — coming 2027 Connect with Kwame: www.americannegotiationinstitute.com

Was macht uns mit sehr hoher Wahrscheinlichkeit gesund – und warum suchen wir trotzdem ständig nach der nächsten Wunderlösung?In dieser Episode ist Dr. Sophie Imhof zu Gast. Sie ist Neurowissenschaftlerin, forscht an der Weill Cornell Medicine in New York, beschäftigt sich mit ALS, Alterung, Epigenetik und Longevity und setzt sich mit ihrem Projekt Wunderwerk Leben und ihren Social-Media-Kanälen für evidenzbasierte Wissenschaftskommunikation ein.Wir sprechen über Bewegung als wahrscheinlich wirksamste "Medizin", warum Gesundheit selten einfache Antworten kennt, weshalb Sophie bewusst keine Produkte bewirbt und warum wissenschaftliches Denken bedeutet, Unsicherheit auszuhalten.Natürlich geht es auch um ihre persönliche Geschichte: vom späten Einstieg ins Laufen über Triathlon und Ultraläufe bis hin zu ihrem Alltag als Forscherin in New York.Eine Episode über Neugier, kritisches Denken und die Faszination des menschlichen Körpers.Themen dieser EpisodeWarum Bewegung wissenschaftlich so gut belegt istGesundheit zwischen Evidenz und Social MediaLongevity, Biohacking & SupplementsProtein-Hype – was sagt die Forschung?Mitochondrien & EnergieproduktionWarum einfache Lösungen so verlockend sindDie Bedeutung von Regeneration und SchlafWissenschaftskommunikation statt ClickbaitLaufen als mentale AuszeitUltraläufe, Wüstenrennen & AbenteuerForschung in New YorkWarum Wissenschaft Unsicherheit aushalten mussDanke liebe Sophie für das wunderbare Gespräch!Mehr zu Dr. Sophie ImhofInstagram https://www.instagram.com/sophie_imhof/Wunderwerk Leben https://wunderwerkleben.com/YouTube https://www.youtube.com/@sophieimhof

The Big Unlock · Dhruv Khullar, M.D., Associate Professor of Medicine and Population Health Sciences, Weill Cornell Medicine In this episode, Dr. Dhruv Khullar, Associate Professor of Medicine and Population Health Sciences at Weill Cornell Medicine, explores how technology, public trust, and the evolving role of physicians are reshaping healthcare. Drawing on his experience as both a practicing clinician and a leading commentator on health policy, he argues that medicine is no longer the singular authority on health. Physicians now share influence with social media, AI tools, direct-to-consumer health companies, and a growing ecosystem of digital health platforms. Dr. Khullar also discusses the promise and pitfalls of AI, emphasizing that while the technology can improve documentation, patient navigation, drug discovery, and clinical decision support, its adoption must be guided by evidence and rigorous evaluation. According to him, AI’s greatest opportunity may be helping restore the human connection in care by removing administrative burdens and creating more space for meaningful patient interactions. The conversation also explores physician education, AI literacy, value-based care, public trust, and the growing commercialization of healthcare. Dr. Khullar returns to a central theme: technology alone will not solve healthcare’s challenges. Progress will require stronger communication, thoughtful leadership, and a renewed commitment to putting patients, not profit, at the center of care. Take a listen. This guest appearance was facilitated through conversations initiated at Health Tech Summit.

Listener feedback on valvular heart disease, statins and frailty, left atrial posterior wall ablation fails again, interpreting medical tests and AI ECG reading are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 II Statins and Frailty Statin Initiation Tied to Lower Frailty Risk in Older Adults https://www.medscape.com/viewarticle/statin-initiation-tied-lower-frailty-risk-older-adults-2026a1000lec Statins and Survival Free of Incident Frailty  https://doi.org/10.1093/eurheartj/ehag451 III LA Posterior Wall Isolation Fails Again CORNERSTONE Trial https://doi.org/10.1093/eurheartj/ehag486 CAPLA Trial https://jamanetwork.com/journals/jama/fullarticle/2800186 IV Does the Display of Test Results Improve Clinical Decisions? Interval Likelihood Ratios for Clinical Decsion-Making https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500249 Making Sense of Health Statistics https://journals.sagepub.com/doi/full/10.1111/j.1539-6053.2008.00033.x V AI and the ECG and Saving Doctors Case Report — AI-Enhanced Diagnostics https://www.nature.com/articles/s41591-026-04454-y The New York Times article https://www.nytimes.com/2026/06/22/health/artificial-intelligence-heart-damage.html You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Dr. Ashley Beecy is the Chief AI Officer at Sutter Health, a cardiologist, and a clinical informaticist. Before joining Sutter, she spent more than a decade at NewYork-Presbyterian and Weill Cornell Medicine, most recently as Medical Director of AI Operations. Her path into medicine took a less common route: she started as a computer systems engineer at IBM, then spent eight years at Citi in operational risk and product management before going to medical school while still working in finance. In this episode of DGTL Voices, Ashley sits down with Ed to talk about what it takes to build an applied AI function inside a major health system. She walks through the three pillars guiding her work at Sutter, why organizational readiness matters as much as the technology itself, and the discipline required to scope and prioritize when the AI news cycle creates a constant pull toward urgency. Plus the seventh-grade math teacher who shaped her trajectory, the mantra her dad gave her about Brinks trucks and funeral processions, and why she defines success today by what teams achieve together rather than individual metrics. https://marxadvisory.com

Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, and a CMS proposal to expand TAVR coverage are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback ICD Trends and Outcomes: 15-Year Analysis https://doi.org/10.1093/europace/euag110 MADIT-RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 II More Long Term Data on TAVR vs SAVR PARTNER 2 Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.03.169 10-Year Outcomes of SAPIEN 3 TAVR or SAVR in Intermediate-Risk Patients https://doi.org/10.1016/j.jacc.2026.03.170 TAVR at a Decade: Editorial https://doi.org/10.1016/j.jacc.2026.04.042 EVOLUT Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 Updated 5-year Outcomes of TAVR vs SAVR in AS https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 NOTION Trial https://doi.org/10.1093/eurheartj/ehae043 PARTNER 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 NOTION 2 Trial https://academic.oup.com/eurheartj/article/45/37/3804/7673297 TAVR vs SAVR Editorial : https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag407/8708044 III The PREVUE-VALVE Study PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 IV CMS has Proposed New Coverage for TAVR CMS Proposal Document https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=321 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Many people worry about memory loss and cognitive decline as they age. In this episode of Health Matters, host Courtney Allison speaks with Dr. Matthew Fink, neurologist-in-chief at NewYork-Presbyterian and Weill Cornell Medicine, about how lifestyle choices—especially diet—can help protect the brain. Dr. Fink explains the MIND diet, a combination of the Mediterranean and DASH diets, which emphasizes whole foods like leafy greens, berries, fish, nuts, and olive oil while limiting salt, sugar, and ultra-processed foods. He breaks down how key nutrients such as B vitamins and antioxidants support brain metabolism, reduce inflammation, and may slow the aging process. The conversation also highlights the brain's high energy demands and why proper nutrition is essential for cognitive function. Dr. Fink shares research showing that healthy lifestyle interventions can significantly lower the risk of dementia and discusses the broader benefits of the MIND diet for heart health and stroke prevention. Finally, Dr. Fink outlines additional habits that support brain health, including regular physical activity, quality sleep, and social connection, emphasizing that even small, gradual changes can lead to meaningful long-term benefits.   Chapters 00:00 – Why Brain Health Is in Your Control How lifestyle choices can reduce dementia risk and why prevention starts early 03:00 – What Is the MIND Diet? Key components of the Mediterranean and DASH diets and how they support the brain 06:00 – Brain-Boosting Nutrients and Foods to Avoid The role of B vitamins, antioxidants, and which foods increase risk 10:30 – Beyond Diet: Exercise, Sleep, and Daily Habits How movement, rest, and social connection contribute to cognitive health     Key Topics Covered MIND diet overview Mediterranean diet and DASH diet Brain metabolism and energy use B vitamins and brain health Antioxidants and inflammation Foods that support cognitive function Foods to limit (salt, sugar, processed foods) Dementia and Alzheimer's prevention Stroke and heart disease connection Exercise and brain function Sleep and cognitive health Lifestyle changes for healthy aging   Takeaway Message You have more control over your brain health than you might think. By focusing on whole, nutrient-rich foods, limiting processed options, staying active, and getting enough sleep, you can significantly reduce your risk of cognitive decline and support a healthier brain as you age.   Doctor Bios Matthew E. Fink, MDis currently the Louis and Gertrude Feil Professor and chair of the Department of Neurology at Weill Cornell Medicine, and neurologist-in-chief at NewYork Presbyterian/Weill Cornell Medical Center.  In addition, he is chief of the Division of Stroke and Critical Care Neurology at NewYork-Presbyterian/Weill Cornell Medical Center, and vice chair of the medical board. Dr. Fink attended college at the University of Pennsylvania, medical school at the University of Pittsburgh, and served as resident and chief resident in internal medicine at the Boston City Hospital. He came to New York and trained in neurology at the Neurological Institute of NewYork-Presbyterian/Columbia University Irving Medical Center, and served as chief resident under Dr. Lewis P. Rowland. Subsequently, he joined the faculty of Columbia University and became the founding director of the Neurology-Neurosurgery Intensive Care Unit at NewYork-Presbyterian and was appointed associate professor of clinical neurology and neurosurgery while at Columbia. Dr. Fink was a founding member and chair of the critical care section of the American Academy of Neurology, and the research section for neurocritical care of the World Federation of Neurology. He is board-certified in internal medicine, neurology, critical care medicine, vascular neurology, and neurocritical care.  He has been elected as a Fellow of the American Neurological Association, the American Academy of Neurology, and the Stroke Council of the American Heart Association. Throughout his career, Dr. Fink has been involved in the education and training of students, residents and fellows in the field of stroke and critical care neurology, as well as an active participant in clinical research within this field. He is a leader in this new specialty, has lectured widely, and has published many research and clinical articles in the field of stroke and critical care. In addition, he currently serves as editor of the monthly publication, NEUROLOGY ALERT, and is a past-president of the New York State Neurological Society.

What can you actually do to keep your brain healthy — and what is just wellness noise? Vanessa talks with Dr. Silky Pahlajani of Weill Cornell Medicine about Alzheimer's, women's brain health, menopause, sleep, stress, depression, hearing, diabetes, and the small habits that may help protect cognition over time.

Today's guest is Kedar Mate, Founder and CMO at Qualified Health. Founded in 2023, Qualified Health AI is a healthcare-native enterprise AI platform helping health systems deploy, govern and scale artificial intelligence safely across clinical, operational and financial workflows. The company provides the infrastructure, governance and expertise needed to turn AI pilots into enterprise-wide transformation, delivering measurable outcomes while maintaining compliance, trust and patient-centered care.Kedar is a recognized leader in healthcare quality, patient safety and health system transformation. He previously served as President and CEO of the Institute for Healthcare Improvement (IHI) and is currently a Professor of Medicine at Weill Cornell Medicine and a Senior Scholar at Stanford University. His career spans healthcare delivery, global public health and policy, including leadership roles with Partners In Health, Brigham and Women's Hospital and the World Health Organization.In the episode, Kedar discusses:0:00 His journey from driven by inequity to founding Qualified Health 4:57 An insight into the company's expert, multidisciplinary team8:33 Building an AI platform to solve healthcare adoption barriers with data, apps and governance13:05 How AI deployment improved workflows, revenue and saves heart patients17:17 Data and governance is key to successful healthcare AI adoption19:58 Why AI healthcare needs cross-disciplinary talent through fast-paced, mission-driven work23:56 How Qualified Health's culture is shaped by leaders' actions, not words

Listener feedback, transcatheter tricuspid valve replacement, a new metabolic disease called CKM, the ARISE-FLUIDS Trial, the BIHCA trial, and temporal trends in ICD therapies are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335 ARREST-AF Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225 POP-AF Trial https://doi.org/10.1093/eurheartj/ehaf689 PRAGUE-25 Trial https://www.jacc.org/doi/10.1016/j.jacc.2025.04.042 II Transcatheter Tricuspid Valve Replacement TRISCEND Cost Study https://doi.org/10.1016/j.shj.2026.101049 TRISCEND II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2401918 III More Disease Creation – the CKM Syndrome ACC/AHA Release First-Ever Guideline for CKM Syndrome https://www.medscape.com/viewarticle/acc-aha-release-first-ever-guideline-ckm-syndrome-2026a1000jbs CKM Guideline in Circulation https://www.ahajournals.org/doi/10.1161/CIR.0000000000001447 IV Two Trials That Teach Important EBM Lessons ARISE-FLUIDS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2516225 Dr Josh Farkas Post on X https://x.com/PulmCrit/status/2065064796270022845?s=20   V  Bicarbonate for Inpatient Cardiac Arrest –The BIHCA trial BIHCA Trial https://jamanetwork.com/journals/jama/fullarticle/2850405 VI The Decline of VT in Heart Failure Trends and Outcomes in ICD Recipients: 15-Year Analysis https://doi.org/10.1093/europace/euag110 Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Chemical cardioversion in the ED, HF monitoring, weight loss in AF, and surgical LAA excision are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Chemical Cardioversion of AF in the ED: The FLECA-ED Trial FLECA-ED Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC10299428/ FLECA-ED ESC Slides https://esc365.escardio.org/presentation/321209 Review on Flecainide Use Despite CAST https://doi.org/10.1016/j.hrthm.2025.08.034 RACE 7 ACWAS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1900353 II Heart Failure Monitoring – The ALLEVIATE-HF Trial ALLEVIATE-HF Trial https://doi.org/10.1016/j.jacc.2026.03.075 CHAMPION Trial https://doi.org/10.1016/S0140-6736(11)60101-3 GUIDE HF Trial https://doi.org/10.1016/S0140-6736(21)01754-2 ALLEVIATE-HF Editorial: Alerts Are Not Treatment https://doi.org/10.1016/j.jacc.2026.04.014 Steve Stiles Medscape report on CHAMPION https://www.medscape.com/viewarticle/755189 III A Negative Weight Loss Study in AF LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335 IV Surgical LAA Excision OPINION Trial https://doi.org/10.1093/eurheartj/ehaf674 LAAOS 3 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2101897 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Tick bites and concerns about Lyme disease are increasing, especially during warmer months. In this episode of Health Matters, host Courtney Allison speaks with Dr. Laura Kirkman and Dr. Karen Acker of NewYork-Presbyterian, Weill Cornell Medicine, and NewYork-Presbyterian Komansky Children's Hospital of Children's Hospital of New York about what people should know about ticks and Lyme disease. Dr. Kirkman explains the types of ticks found in the U.S., where they live, and how they attach to the body. She emphasizes that not every tick bite leads to Lyme disease—it depends on the tick species, whether it carries the bacteria, and how long it remains attached. Dr. Acker explains how Lyme disease is transmitted and outlines the stages of infection, including early symptoms such as the characteristic bullseye rash, fever, and fatigue, as well as less common complications involving the nervous system, heart, or joints. The conversation also covers how Lyme disease is diagnosed and treated, including when testing is necessary and when a preventive dose of antibiotics may be recommended after a tick bite. Finally, the doctors share practical strategies to prevent tick bites—from tick checks and proper clothing to repellents and safe tick removal—and discuss emerging concerns like lone star ticks and alpha-gal syndrome. Their key message: with awareness and simple precautions, you can significantly reduce your risk.   Chapters 00:00 – Understanding Ticks and Their Risks Overview of tick species, where they live, and how they interact with humans 04:30 – What Is Lyme Disease? How Lyme disease is transmitted, early symptoms, and stages of infection 08:45 – Diagnosis, Treatment, and Tick Removal When to test for Lyme disease, antibiotic options, and how to safely remove a tick 12:00 – Preventing Tick Bites and Emerging Concerns Prevention strategies, protecting kids and pets, and lone star tick risks   Key Topics Covered Tick species in the U.S. Where ticks live and how they attach Lyme disease transmission Early symptoms of Lyme disease Bullseye rash and warning signs Diagnosis and antibody testing Antibiotic treatment and prevention Proper tick removal techniques Tick bite prevention strategies Lone star tick and alpha-gal syndrome Takeaway Message A tick bite does not automatically mean Lyme disease. By checking for ticks regularly, removing them promptly, and using simple prevention strategies, you can significantly reduce your risk. When caught early, Lyme disease is highly treatable—making awareness and prevention your best tools for staying safe outdoors.   Doctor Bios Dr. Laura Kirkman is a physician-scientist whose research focuses on the molecular pathogenesis of infection with bloodborne parasitic diseases: malaria and babesiosis. Dr. Kirkman received her M.D. from the Albert Einstein College of Medicine with distinction in research where she benefitted from support from a Howard Hughes Medical Student research award. She completed her clinical training in internal medicine at Yale-New Haven Hospital and her infectious disease fellowship at the NewYork-Presbyterian/Weill Cornell Medical Center. She is an associate professor of medicine and microbiology and immunology at Weill Cornell Medicine.   Dr. Karen Acker is a pediatric hospital epidemiologist at NewYork-Presbyterian Komansky Children's Hospital of Children's Hospital of New York, and an assistant professor in clinical pediatrics at Weill Cornell Medicine. She received her medical degree from SUNY Downstate Medical Center followed by a residency in pediatrics at NewYork-Presbyterian/Weill Cornell Medical Center. After completing her fellowship in pediatric infectious diseases at NewYork-Presbyterian/Columbia University Irving Medical Center in 2018, she joined the pediatric infectious disease division at Weill Cornell Medicine, and has served as a hospital epidemiologist since 2019. Her clinical and research interests include the epidemiology of infectious outbreaks and healthcare-associated infections, diagnostic stewardship, Staphylococcus aureus infections, respiratory viral infections in children, and factors influencing vaccine uptake in children. Dr. Acker is board-certified in pediatrics and board-certified for pediatric infectious diseases.

A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in cardiac amyloidosis, and a lipid guideline rebuttal are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Permanent Lipid Lowering therapy Verve 102 Therapy for FH https://www.nejm.org/doi/full/10.1056/NEJMoa2601283 II Vesalius Substudy on PCSK9i Use in Patients With Previous PCI VESALIUS Subgroup Analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.080616 VESALIUS Study - NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 III Tirzepatide looking to be best again SURPASS-EARLY Trial https://www.acpjournals.org/doi/10.7326/ANNALS-25-05602 SURMOUNT-5 Trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394 IV Arrhythmias in Cardiac Amyloidosis Loop Recorders Reveal Arrhythmias in Cardiac Amyloidosis https://www.medscape.com/viewarticle/loop-recorders-reveal-arrhythmias-cardiac-amyloidosis-2026a1000gq9 EXCALIBUR Study https://www.jacc.org/doi/10.1016/j.jacc.2026.04.030 V Lipid Guidelines ·       In Defense of the 2026 Dyslipidemia Guideline https://www.medscape.com/viewarticle/defense-2026-dyslipidemia-guideline-2026a1000hd0 Lipid Guidelines: Four Major Concerns https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

What if the persistent pelvic pain, the performance issues in the bedroom, or that nagging brain fog isn't just a physical "glitch," but a physical manifestation of an underlying mental struggle? Most men are trained to wear a mask in the clinic, but the body always keeps the score. When a man avoids reality, his physiology pays the price.Today, we're peeling back that mask with Dr. Daniel Margolis. Dr. Margolis is an Associate Professor of Radiology at Weill Cornell Medicine in New York City and a world-renowned diagnostic radiologist. A graduate of UC Berkeley and USC, he completed advanced fellowships at Stanford and UCLA, specializing in using MRI to detect and characterize prostate cancer. With over 90 publications to his name, Dr. Margolis serves on the ACR PI-RADS Committee and Co-Chairs the Society of Abdominal Radiology Prostate Cancer Panel. He isn't just someone who looks at screens; he's the "driver" of the most advanced imaging "cars" in the world. If you've been worried about Gadolinium brain deposits or simply want to know if you can skip the needle during your next scan, this is the masterclass you've been waiting for.In this episode, you'll learn:The Biparametric Breakthrough: Why most men can now skip MRI contrast without missing significant cancer.1.5T vs. 3T: Why a "stronger" magnet isn't always better, especially if you have a hip replacement.The Biopsy-Free Future: How AI and blood tests are converging to eventually eliminate the needle.Expert Vetting: How to tell if your radiologist is a "pro" or just a "tech" by looking for ACR certification.Chapters00:00 – Intro & Why MRI Matters in Prostate Cancer02:45 – How Many MRIs Does a Radiologist Read a Day?06:20 – Will AI Replace Radiologists?11:20 – The PRIME Trial: Can We Skip MRI Contrast Dye?14:15 – 1.5 Tesla vs 3 Tesla MRI: Does It Matter?22:45 – How to Know if You're Getting a Good Prostate MRI24:00 – Multiparametric vs Biparametric MRI Explained35:00 – PRIME Trial Results: Did Contrast Actually Matter?38:15 – Is Gadolinium Contrast Safe?44:20 – Why the PRIME Trial Worked: Quality Control Matters48:00 – Who Still Needs Contrast on Their MRI?56:00 – Will Prostate Biopsies Disappear?59:00 – How AI is Changing Prostate MRI___________________________________

Jonathan Avery, M.D., is the Vice Chair for Addiction Psychiatry, the Stephen P. Tobin and Dr. Arnold M. Cooper Professor in Consultation-Liaison Psychiatry, and the Program Director for the Addiction Psychiatry Fellowship at Weill Cornell Medicine and New York-Presbyterian Hospital.  He is also the medical director for the NBA/NBPA's Anti-Drug Program. Today on the show we discuss: why today's weed is far more potent and risky than the marijuana many people grew up hearing about, how high-THC products can impact anxiety, depression, sleep, psychosis, withdrawal, and cannabinoid hyperemesis syndrome, why cannabis addiction is often dismissed and misunderstood, how social media is rewiring kids' brains through dopamine-driven attention loops, why porn, OnlyFans, AI girlfriends, and loneliness are becoming a major crisis for young men, and how sports betting has become one of the fastest-growing behavioral addictions because of constant access through phones and much more. ⚠ WELLNESS DISCLAIMER ⚠ Please be advised; the topics related to health and mental health in my content are for informational, discussion, and entertainment purposes only. The content is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek the advice of your health or mental health professional or other qualified health provider with any questions you may have regarding your current condition. Never disregard professional advice or delay in seeking it because of something you have heard from your favorite creator, on social media, or shared within content you've consumed. If you are in crisis or you think you may have an emergency, call your doctor or 911 immediately. If you do not have a health professional who is able to assist you, use these resources to find help: Emergency Medical Services—911 If the situation is potentially life-threatening, get immediate emergency assistance by calling 911, available 24 hours a day. National Suicide Prevention Lifeline, 1-800-273-TALK (8255) or https://suicidepreventionlifeline.org.  SAMHSA addiction and mental health treatment Referral Helpline, 1-877-SAMHSA7 (1-877-726-4727) and https://www.samhsa.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

Three more digoxin trials, yet another GLP-1 drug on the horizon, vagal nerve stimulation, trial inside baseball, and more on lipid guidelines are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I More About Low-dose Digoxin in HF — The DECISION Trial(s) DECISION Trial https://www.nature.com/articles/s41591-026-04406-6 Digitalis Glycosides in HF — JAMA Meta-Analysis https://jamanetwork.com/journals/jama/fullarticle/2848972 DIGIT-HF Trial https://www.nejm.org/doi/10.1056/NEJMoa2415471 RADIANCE Trial (1993) https://www.nejm.org/doi/full/10.1056/NEJM199307013290101 DECISION Withdrawal Study https://doi.org/10.1093/eurheartj/ehag385 Digoxin Discontinuation vs Continuation in Chronic HF https://doi.org/10.1016/j.amjcard.2007.02.099 II Yet another GLP-1 Drug Announced this Week Lillly News Release on Retatrutide https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss III A Big Story in HF Science – Vagal Nerve Stimulation in HFrEF ANTHEM HFrEF trial https://doi.org/10.1016/j.jacc.2026.03.040 Editorials An Unfinished ANTHEM https://doi.org/10.1016/j.jacc.2026.04.033 When Trials Stop Prematurely https://doi.org/10.1016/j.jacc.2026.03.039 IV Lipid Guideline News Lipid Guidelines: Four Major Concerns https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim Editorial: Time to Move Beyond the Statin Nocebo Effect  https://www.jacc.org/doi/10.1016/j.jacc.2026.04.002 Correspondence: SAMSON N-of-1 Trial of Statin, Placebo, or No Treatment https://www.nejm.org/doi/full/10.1056/NEJMc2031173 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Another positive digoxin trial, another classic coronary physiology study from Imperial College London (ORBITA-FIRE), news in hypertrophic cardiomyopathy, and TAVR done in the wrong patients are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Digoxin in Rheumatic Heart Disease Dig-RHD Trial https://jamanetwork.com/journals/jama/fullarticle/2848973 Safety and Efficacy of Digoxin: Meta-Analysis https://www.bmj.com/content/351/bmj.h4451.long DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471 DIG Trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801 RADIANCE Trial https://www.nejm.org/doi/full/10.1056/NEJM199307013290101 II The Physiologic Threshold for Angina ORBITA-FIRE Trial https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.078738 III Prediction in Hypertrophic Cardiomyopathy Predictors of Long-Term Outcomes in HCM https://jamanetwork.com/journals/jama/fullarticle/2848800#250998713 IV TAVR Trends in Young Patients Temporal Trends in AVR for Aortic Stenosis in Patients < 65 https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016826 Wall Street Journal article https://www.wsj.com/health/healthcare/heart-valve-tavr-surgery-aorta-1e0eda70 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback from the DanGer Shock investigators, complete vs staged revascularization, polygenic risk scores, and quality improvement failure in an RCT are the topics John Mandrola, MD, discusses in this week's podcast.   This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback DanGer Shock Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 CHIP-BCIS 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2515704 II Immediate Complete vs Staged Revascularization in STEMI Meta-analysis: Timing of Complete Revasc in Patients with STEMI and Multivessel Disease https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016601 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918 III Polygenic Risk Scores for Prediction Polygenic Risk Report in US-Based Hospitals for 8 CV Conditions  https://www.jacc.org/doi/10.1016/j.jacc.2026.03.035 IV Practice Improvement Policies Undergo the Proper Test – Randomization Quality Improvement on Hospitalizations and Health Outcomes for People with CHD https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012904 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored the nuances of choosing between single-agent and dual checkpoint inhibitors, the role of PD-L1 scores, and the impact of molecular testing on treatment decisions. Special guest Dr. Christine Garcia, a thoracic medical oncologist and fellowship program director at Weill Cornell Medicine, shared her insights on the importance of biomarker testing, the implications of STK11 and KEAP1 mutations, and the evolving landscape of KRAS inhibitors. Key topics covered in this episode: The significance of NGS testing and PD-L1 scores in treatment decisions The role of chemotherapy in high PD-L1 patients Insights on dual checkpoint inhibitors based on recent clinical trials The latest options for KRAS G12C mutations and C-MET overexpression Practical considerations for managing treatment-related side effects Tune in for an informative discussion that bridges the gap between academic research and community practice in oncology. Don't forget to subscribe for more episodes on treatment algorithms and the latest in cancer care! #MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

Three years after her small cell lung cancer diagnosis, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, medical oncologist at Weill Cornell Medicine, to talk about the rapid changes transforming SCLC care. From immunotherapy and bispecific T-cell engagers to emerging targeted therapies, this episode unpacks what every patient should know about today's treatment landscape. You'll learn why clinical trials are NOT a last resort, why you should ask about them at your very first appointment, and how to advocate for yourself through side effects and treatment decisions. Dr. Saxena also explains the evolving role of biomarker testing in small cell lung cancer and shares why he's more hopeful than ever about patient outcomes. Whether you're newly diagnosed, a long-term survivor, or a caregiver, this conversation delivers honest answers and real hope. Guests: Dr. Ashish Saxena, Medical Oncologist, Weill Cornell Medicine Wendy Brooks, Patient Co-Host, Living with Small Cell Lung Cancer Show Notes: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-SCLC-Clinical-Trials-Long-Term-Outlook-Show-Notes.pdf  Transcript: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-SCLC-Clinical-Trials-Transcript.pdf  Video: https://youtu.be/RCwJvdcOS-4  For more information, visit lcfamerica.org.

Time to quadruple therapy, the disappointing AVANT GUARD trial, PFA risks, the TREAT-PVC trial, and NSTEMI care in the frail elderly are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Time to Quadruple Therapy in HFrEF Time to Quadruple Therapy After Diagnosis of HFrEF https://jamanetwork.com/journals/jamacardiology/fullarticle/2846899 II AVANT GUARD PFA Bests Meds as First-Line Treatment for Persistent AF in Randomized Trial https://www.medscape.com/viewarticle/pulsed-field-ablation-bests-meds-first-line-treatment-2026a1000dsm Pulsed Field Ablation of AF Disappoints in Setup for Success: AVANT GUARD https://www.medscape.com/viewarticle/pulsed-field-ablation-af-disappoints-setup-success-avant-2026a1000ddt AVANT GUARD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600929 Persistent AF: Meta-analysis of Invasive Strategies 10.1016/j.ijcard.2018.11.127 External Link III Speaking of Scary News on PFA – The TIFFANY Study Abstract - The TIFFANY Study https://www.heartrhythmjournal.com/article/S1547-5271(26)01747-9/fulltext Delayed Myocardial Ischemia and Malignant Arrhythmias After PFA https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.077983 Alberto Alfie Comment https://x.com/ALFIEEP1/status/2050029151315189774?s=20 IV TREAT PVC Trial TREAT-PVC Trial https://doi.org/10.1016/j.jacep.2026.01.011 TREAT-AF Study 2020 https://doi.org/10.1016/j.jacep.2019.11.008 V NSTEMI In Frail Older Patients SENIOR-RITA Trial https://www.nejm.org/doi/10.1056/NEJMoa2407791 Subanalysis of Senior RITA Trial https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2847995 Timing of Invasive Strategy in Patients With Non-ST-Elevation Acute Coronary Syndrome -- Meta-analysis https://doi.org/10.1016/S0140-6736(17)31490-3 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This episode recorded live at the Becker's 16th Annual Meeting features Keith Elgart, Chief Executive Officer, Concierge Choice Physicians and Timothy P. Seibert, MPH Chief Administrative Officer & Executive Director — Primary Care Initiative, Weill Cornell Medicine. They discuss how hybrid concierge programs can improve physician satisfaction, enhance patient experience, and create sustainable revenue streams while maintaining equitable access to care.This episode is sponsored by Concierge Choice Physicians.

PCSK9 inhibitors in high-risk diabetes without ASCVD, the CAAN-AF trial, conduction system pacing vs biventricular pacing, PFA and stroke, and therapeutic fashion infects expert consensus are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I VESALIUS-CV  VESALIUS-CV Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 JAMA Substudy https://jamanetwork.com/journals/jama/fullarticle/2847162 II How Best to Maximize CRT Benefit in Patients with AF CAAN-AF Trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag206/8654625?searchresult=1 Role of AV Node Ablation: Meta-analysis of Observational Studies https://www.jacc.org/doi/10.1016/j.jacc.2011.10.891 III Stroke Rates in PFA vs Thermal Ablation Comparative Safety of RF versus PFA for AF in a High-Volume US Medical Center https://esc365.escardio.org/Ehra-congress/sessions/18281 IV Five New CSP Studies Presented and Published HeartSync-LBBP Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2845803 PhysioSync-HF Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2845802 LEFT-BUNDLE-CRT Trial https://doi.org/10.1093/eurheartj/ehag225 Long-Term Follow-up of His-Alternative I Trial https://www.jacc.org/doi/10.1016/j.jacep.2026.02.016 LECART Trial https://esc365.escardio.org/Ehra-congress/sessions/17140 V New EP Training Document Published Advanced Training Statement on Clinical Cardiac Electrophysiology  https://www.jacc.org/doi/10.1016/j.jacc.2026.01.074 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Show Notes Inflammation is one of the body's most important defense mechanisms—but when it doesn't shut off, it can quietly contribute to serious health problems. In this episode of Health Matters, host Courtney Allison speaks with Dr. Charis Meng, a rheumatologist at NewYork‑Presbyterian and Weill Cornell Medicine, about how inflammation works and why chronic inflammation can put the body at risk. Dr. Meng explains the difference between short‑term, helpful inflammation and long‑term inflammation that lingers for months or years, affecting everything from joints to the heart, brain, and immune system. The conversation explores autoimmune conditions like rheumatoid arthritis, what causes inflammation, and how lifestyle factors such as diet, sleep, stress, and physical activity can impact inflammation. Dr. Meng also discusses treatment options ranging from targeted immune therapies to lifestyle changes, acupuncture, and emerging research on GLP‑1 medications. This episode offers clear, science‑based guidance to help listeners understand inflammation—and what they can do to help keep it in check. Chapters 00:00 – What Is Inflammation, and When Is It Helpful? How inflammation works as the body's natural defense system 03:45 – Acute vs. Chronic Inflammation Why inflammation sometimes doesn't shut off—and how it can cause harm 07:30 – Inflammation and Disease Risk Autoimmune conditions, heart disease, diabetes, and cancer 09:45 – How to Reduce Chronic Inflammation Medical treatments, diet, exercise, sleep, and emerging research   Key Topics Covered Inflammation and the immune system Acute vs. chronic inflammation Autoimmune diseases and rheumatoid arthritis Heart disease, diabetes, and cancer risk Anti‑inflammatory lifestyle habits Mediterranean diet and inflammation Exercise, sleep, and immune balance Acupuncture and integrative care GLP‑1 medications and inflammation research   Takeaway Message Inflammation is the body's natural healing response, but when it becomes chronic and doesn't turn off, it can contribute to serious conditions like heart disease, diabetes, and cancer. While some chronic inflammation is driven by autoimmune disease or factors beyond our control, healthy habits like diet, exercise, and sleep can still help support the body and reduce long-term health risks.   Doctor Bio Dr. Charis Meng is an assistant attending rheumatologist at NewYork-Presbyterian/Weill Cornell Medical Center and an assistant professor of clinical medicine at Weill Cornell Medicine, who is also certified in acupuncture. Her practice is in general rheumatology, and her special interests are in treating older patients with chronic pain, low back pain and inflammatory arthritis.

SPIRIT-HF, another spironolactone trial in HFpEF; the ESSENCE imaging study of the drug olezarsen; the SirPAD trial in peripheral artery disease; and ultrasound-guided femoral venous access are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I ACC: SPIRIT-HF Trial FINEARTS-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2407107 TOPCAT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1313731 TOPCAT Americas Trial https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255 II A New Class of Lipid Lowering Drug Has a Dubious Debut At ACC ESSENCE-TIMI 73b Imaging Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.080012 ESSENCE-TIMI 73b Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2507227 IMPROVE IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1410489 III Drug-Coated Balloons Looked Quite Good in PAD interventions Sirolimus-Coated Balloon Reduces Amputation Risk in Peripheral Artery Disease https://www.medscape.com/viewarticle/sirolimus-coated-balloon-reduces-amputation-risk-peripheral-2026a1000a83 SirPAD trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600360 IV Another Vascular Story from the European Heart Rhythm Association ULYSSES Trial https://doi.org/10.1093/eurheartj/ehag291 ULTRA-FAST Trial https://doi.org/10.1093/europace/eux175 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this episode of the Neurocritical Care Society Podcast Masterclass series, hosts Stephan Mayer, MD, FCCM, FNCS, and Jon Rosenberg, MD, are joined by Hooman Kamel, MD, MS, professor of neurology at Weill Cornell Medicine, to discuss how clinical trials take shape in practice. Dr. Kamel reflects on his path into research, the importance of strong mentorship and what it takes to grow from early-stage projects to large multicenter trials. Their conversation explores practical aspects of trial design in neurocritical care, including building robust data sets, leveraging EMR-based tools, designing pragmatic studies and fostering collaboration across institutions. They also discuss the Arcadia trial and the broader mindset required to stay engaged in research, even when results do not go as expected. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

Three imaging-guided PCI trials (two with surprising results), LDL targets, an oral PCSK9 inhibitor, and another beta-blocker withdrawal trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I IVUS-Guided PCI OPTIMAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600440 IVUS-CHIP Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601521 ILUMIEN IV Trial https://www.nejm.org/doi/10.1056/NEJMoa2305861 DKCRUSH VIII Trial https://doi.org/10.1016/j.jacc.2026.01.081 II Ez-PAVE Trial — Low vs Very Low LDL-targets Does Ez-PAVE Support 'Lower Is Better' for LDL-C? https://www.medscape.com/viewarticle/does-ez-pave-support-lower-better-ldl-c-2026a1000akx Ez-PAVE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600283 2026 ACC/AHA Lipid Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423 III CORALreef AddOn CORALreef AddOn Trial https://www.jacc.org/doi/abs/10.1016/j.jacc.2026.03.036 This Week in Caardiology 2-6-26 https://www.medscape.com/viewarticle/1003240 CORALreef Lipids Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002 IV Another Post-MI Beta-blocker Withdrawal Study: SMART-DECISION SMART-DECISION Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601005 ABYSS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

John Mandrola offers an ACC recap of 5 big trials—Hi-PEITHO, PROTAVI, ORBITA-CTO, CHIPS-BCIS3 and CHAMPION AF This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Catheter Based Fibrinolysis of Pulmonary Embolism –Hi PEITHO Fibrinolysis Treatment Validated in Large Trial for Acute Intermediate-Risk PE https://www.medscape.com/viewarticle/fibrinolysis-treatment-validated-large-trial-acute-2026a10009im Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism (HI PEITHO) https://www.nejm.org/doi/full/10.1056/NEJMoa2516567 National Early Warning Score (NEWS) https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/ II PRO-TAVI trial Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI) 10.1016/S0140-6736(26)00308-9 External Link PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation (Notion 3) https://www.nejm.org/doi/full/10.1056/NEJMoa2401513 III ORBITA CTO Sham vs PCI for Angina Relief Tightly Blinded Trial Confirms PCI Reduces Angina in Obstructive Occlusion https://www.medscape.com/viewarticle/tightly-blinded-trial-confirms-pci-reduces-angina-2026a10009ob A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina - ORBITA-CTO https://www.jacc.org/doi/10.1016/j.jacc.2026.03.027 ORBITA 1 10.1016/S0140-6736(17)32714-9 External Link ORBITA 2 https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 DECISION CTO https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.031313 EuroCTO https://doi.org/10.1093/eurheartj/ehy220   IV CHIPS BCIS3 Impella Supported High-Risk PCI Adoption Before Evidence: CHIP-BCIS3 Humbles Impella https://www.medscape.com/viewarticle/adoption-before-evidence-chip-bcis3-humbles-impella-2026a10009jh Left Ventricular Unloading in High-Risk PCI (CHIP BCIS3) https://www.nejm.org/doi/full/10.1056/NEJMoa2515704 Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock) https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 V CHAMPION AF – Watchman vs DOAC in Patients With AF CHAMPION-AF Trial Finds LAAC an Alternative for NOAC in Lower-Risk Patients https://www.medscape.com/viewarticle/champion-af-trial-finds-laac-alternative-noac-lower-risk-2026a10009ij Six Reasons Why CHAMPION-AF Should Not Change Practice https://www.medscape.com/viewarticle/six-reasons-why-champion-af-should-not-change-practice-2026a10009i7 Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation (CHAMPION AF) https://www.nejm.org/doi/full/10.1056/NEJMoa2517213 Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (CLOSURE AF) https://www.nejm.org/doi/full/10.1056/NEJMoa2513310 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Clinical trials can feel intimidating, but they are one of the most important ways new lung cancer treatments become available to patients. In this episode of Hope With Answers: Living With Lung Cancer, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, thoracic medical oncologist at Weill Cornell Medicine, to break down what clinical trials really are and why they matter. Together, they discuss when patients should ask about clinical trials, what to expect when participating, and common misconceptions — including the fear of being a “guinea pig.” Dr. Saxena explains how clinical trials are carefully designed, closely monitored, and often provide access to promising new therapies earlier in the treatment journey. You'll learn: What clinical trials are and how they work Why timing matters and why you should ask early What patients actually receive in a clinical trial How clinical trials are improving outcomes in lung cancer What questions to ask your doctor Whether you're newly diagnosed or exploring your options, this conversation offers clear, practical insight to help you better understand clinical trials and your role in the decision-making process. Show Notes: https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-HWA-Clinical-Trials-Show-Notes-2026Spring.pdf  Transcript: https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-HWA-Clinical-Trials-Transcript-2026Spring.pdf  Watch Video: https://youtu.be/kBfh8EAGey8  To learn more about clinical trials and download the free toolkit, visit https://lcfamerica.org/trials.

Lawrence Casalino is a professor of population health sciences at Weill Cornell Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Casalino. Physicians, Corporatization, and the Unmeasured Quality of Care. N Engl J Med 2026;394:1249-1251.

Early aortic valve replacement in aortic stenosis, left atrial appendage occlusion in JAMA Cardiology, and a big preview of the upcoming American College of Cardiology meeting are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Early AVR RECOVERY Trial at 10 Years https://www.nejm.org/doi/full/10.1056/NEJMoa2511920 II Major Bleeding with Amulet and Watchman in JAMA Cardiology Amulet IDE Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2847047 5-year Results From Amulet IDE  https://www.jacc.org/doi/10.1016/j.jacc.2024.10.101 III ACC Preview Mandrola's Top 4 Trials from ACC 2026: Details Matter https://www.medscape.com/viewarticle/mandrolas-top-4-trials-acc-2026-details-matter-2026a10008ti CHIB-BCIS3 Trial https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.123.013367 Champion-AF Protocol https://doi.org/10.1016/j.ahj.2023.05.022 ORBITA-CTO Protocol Paper https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1172763/full SPIRIT-HF Clinical Trials.gov  https://clinicaltrials.gov/study/NCT04727073 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

"A side effect patients might experience is lymphedema. This is an increased buildup of lymphatic fluid in the tissues, either in the breast or in the arm and hand of the affected side. It's quite problematic for women. They might feel self-conscious. It might feel uncomfortable that the arm feels like it's throbbing or heavy. Clothing may not fit quite right. So we're always on the lookout for lymphedema," Maria Fenton-Kerimian, APRN, AOCNP®, nurse practitioner at Weill Cornell Medicine in New York, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation site-specific side effects in breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 27, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to side effects experienced with radiation therapy to the breast. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Could High-Dose Radiation Be the Missing Link in Breast Cancer Immunotherapy? Exercise Program Improves Quality of Life in Patients With Breast Cancer—and Keeps Them Moving Daily Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer How to Handle Even the Worst Radiation Therapy Side Effects Clinical Journal of Oncology Nursing articles: Instruments to Evaluate Self-Management of Radiation Dermatitis in Patients With Breast Cancer The Effects of a Clinical Care Model on Quality Process Outcomes in Radiation Oncology Oncology Nursing Forum articles: Feasibility of Breast Radiation Therapy Video Education Combined With Standard Radiation Therapy Education for Patients With Breast Cancer ONS Guidelines™ for Cancer Treatment–Related Radiodermatitis ONS books:  Guide to Breast Care for Oncology Nurses Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS/ONCC® courses:  Radiation Oncology Conference Recordings Bundle™ Radiation Therapy Certificate™ ONS Huddle Cards: Altered Body Image Late Effects of Cancer Treatment Radiation Sexuality ONS Guidelines™: Cancer Treatment–Related Lymphedema Cancer Treatment–Related Radiodermatitis ONS Learning Libraries: Breast Cancer Radiation American Society for Radiation Oncology (ASTRO) National Comprehensive Cancer Network home page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The goals of radiation to the breast are typically broken out into three different rationales. Either adjuvant treatment, where the tumor is removed surgically from the breast first and then radiation is delivered to lower the likelihood of return of the cancer. And then the second way it's given is with a curative intent. That may be for tumors that couldn't be fully resected, and the hope is to eradicate the tumor that is still present in the tissue. Lastly, it can be given in a palliative fashion where you're not expecting to completely cure the person of the cancer, but you hope to shrink the tumor enough to relieve symptoms." TS 1:46 "We really try to focus on patients managing fatigue by ensuring that they're having an appropriate, balanced diet with proper macro and micronutrients and that they're having adequate protein intake. We encourage patients to get adequate sleep. There is a culture of people pushing themselves and working into late hours of the night, and this would be quite difficult if you're experiencing radiation-induced fatigue. If someone is familiar and does regular exercise, we highly encourage them to continue that. If someone has not done much exercise and has slipped into a little bit of deconditioning or they're older or more frail, we might refer them for physical therapy or strength training to rebuild some of that stamina and energy." TS 7:56 "One of the key products to use for prevention of radiation dermatitis are silicone patches, and there are many on the market that are worn during the course of radiation or when the skin reaction begins. And they could stay on for several days during treatment, even if you're gently showering around the area. There are many homeopathic creams made from calendula flower, aloe vera, or some kind of combination of these types of products. The real issue with these products is that many of them aren't covered by insurance, so patients have to buy them out of pocket, over the counter. For some of our patients who are more financially challenged, it may be a problem. So I think [it's important] to be familiar with many different products so that patients have access to something that will minimize their skin reaction." TS 14:48 "After 90 days, it may be more common to see some of the cosmetic changes that can happen in the soft tissue of the breast. One of them is radiation fibrosis, which can be like a diffused scar tissue in the breast. It can sometimes cause hardening, retraction, or asymmetry. Sometimes it can cause a tight feeling where people can't stretch their arm to the full extent. We also know that there can be slower healing if surgery is done. For people that have tissue expanders or still want to have corrective plastic surgery, we really encourage them to wait at least six months or longer before approaching any of those plastic surgery procedures." TS 19:55 "Sexual health is such a big topic, but I think that nurses in radiation oncology are in a very good position to discuss that because we see patients for repeated period of time. So, there's maybe a quicker intimacy or familiarity that happens with the nurses in radiation. Personally, I always bring it up at a follow-up visit, which we do about a month after radiation ends. And it's kind of because the dust is settling and people are getting back to their lives." TS 23:53

What does your gut really do—and how can you keep it healthy? In this episode of Health Matters, host Courtney Allison sits down with Dr. Haley Zylberberg, a gastroenterologist at NewYork‑Presbyterian and Weill Cornell Medicine, to find out the basics of gut health, from digestion and the microbiome to fiber, fermented foods, and the gut‑brain connection. Dr. Zylberberg explains how fiber supports digestion, why everyone's “normal” gut function looks different, and how stress and mental health can directly affect the digestive system. She also shares signs of a healthy gut, red flags that shouldn't be ignored, and why colorectal cancer screening is so important—especially as younger adults are being diagnosed more often. Whether you're curious about probiotics, wondering how much fiber you really need, or looking to better understand your body, this episode offers practical, science‑backed guidance to help support lifelong gut health. Chapters: 00:00 – The Basics of Gut Health and the Microbiome What the gut is, how digestion works, and why the microbiome plays a critical role in overall health. 06:30 – Fiber, Food, and Supporting Your Gut How fiber supports digestion, how much you need each day, common misconceptions, and tips for increasing fiber safely. 11:30 – The Gut‑Brain Connection How stress affects digestion, why the gut and brain communicate so closely, and what that means for digestive symptoms. 15:10 – Red Flags and Colorectal Cancer Screening Warning signs of an unhealthy gut, when to see a doctor, and why colorectal cancer screening is essential and preventive. Key Topics Covered   ·  Gut anatomy and digestion ·  The gut microbiome and “good” bacteria ·  Fiber benefits and daily fiber intake ·  Fermented foods and probiotics ·  Gas, bloating, constipation, and diarrhea ·  The gut‑brain connection and stress ·  Red flag digestive symptoms ·  Colorectal cancer prevention and screening guidelines Takeaway Message Your gut plays a central role in your overall health, and small, consistent habits—like eating enough fiber, managing stress, and knowing what's normal for your body—can make a big difference. Paying attention to changes and staying up to date with recommended screenings can help catch problems early and even prevent serious disease. Expert Guest Dr. Haley Zylberberg's clinical focus is general gastroenterology, with a specialization in celiac disease. She has a sustained interest in patient-outcomes research using large databases and has authored numerous peer-reviewed articles on celiac disease diagnosis and its clinical manifestations.  Dr. Zylberberg earned her B.A. in neuroscience and behavior from Columbia University and her medical degree at Hofstra-Northwell School of Medicine, where she graduated with a distinction in research. She completed internal medicine residency at The Mount Sinai Hospital, followed by a gastroenterology fellowship at NewYork-Presbyterian/Columbia University Irving Medical Center, where she served as chief fellow. During her fellowship, Dr. Zylberberg undertook advanced training in research methods, culminating in a master's degree in patient-oriented research from Columbia's Mailman School of Public Health.

Listener feedback, the huge CLOSURE-AF trial of LAAC vs best medical therapy, previews of CHAMPION AF, and the controversial ACC/AHA lipid treatment guidelines are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703 Closure AF published in NEJM CLOSURE-AF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513310 CHAMPION AF Rationale - Watchman FLX vs DOACs in Patients With AF https://pubmed.ncbi.nlm.nih.gov/37279840/ LIPID Guidelines ACC/AHA Joint Committee Guideline on Management of Dyslipidemia https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Welcome to the Oncology Brothers podcast! In this episode, we discussed the current treatment landscape for prostate cancer, featuring special guest Dr. Scott Tagawa, a GU Medical Oncologist from Weill Cornell Medicine. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explored: The current standard of care for localized prostate cancer, including active surveillance, surgery, and radiation. The significance of ADT and abiraterone in high-risk disease, supported by the STAMPEDE trial. The role of PSMA PET/CT in staging and how it impacts treatment decisions. Treatment options for castration-sensitive and castration-resistant prostate cancer, including the use of ARPi and chemotherapy. The importance of germline and somatic testing, especially with the recent approval of Niraparib for BRCA2-positive disease. Insights on managing side effects and the nuances of patient-centered care in oncology. Whether you're a healthcare professional or someone interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help you stay informed. Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #ProstateCancer, #ADT, #PSMA, #PARPinhibitor, #OncologyBrothers

Beta-blocker in non-obstructive hypertrophic cardiomyopathy, a head-to-head apixaban vs rivaroxaban RCT, diltiazem vs metoprolol combined with DOAC, and the accuracy of smart watches for AF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback EMPATICC trial https://academic.oup.com/eurheartj/article/47/9/1034/8242490 II Beta-blocker in Non-obstructive HCM BB vs Calcium Channel Blocker in Non-obstructive HCM https://doi.org/10.1016/j.jacc.2025.11.028 RCT of Metoprolol in Patients With Obstructive HCM https://doi.org/10.1016/j.jacc.2021.07.065 III Apixaban vs Rivaroxaban for Bleeding Risk COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703 AMPLIFY Trial (Apixaban) https://www.nejm.org/doi/10.1056/NEJMoa1302507 EINSTEIN Trial (Rivaroxaban) https://www.nejm.org/doi/full/10.1056/NEJMoa1007903 IV Diltiazem vs Metoprolol When Combined with DOAC Risk for Bleeding in AF Patients Using Apixaban or Rivaroxaban With Diltiazem https://www.acpjournals.org/doi/10.7326/ANNALS-25-01408 V Actual Clinical Use of Smart Watches CIRCA-DOSE Original Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042622 Wearable Smartwatches for AF Detection After Ablation https://doi.org/10.1093/europace/euaf280 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, urgent AF ablation, AF ablation as a stroke-reducing therapy, implantable loop recorder accuracy, and HF management in the setting of serious disease are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Urgent AF ablations Urgent vs Elective AF Ablation in the US  https://www.jacc.org/doi/10.1016/j.jacep.2025.12.030 II AF Ablation Is Not Likely a Good Therapy for Stroke Reduction STABLED Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845745 Catheter Ablation for AF Associated With Lower Incidence of Stroke https://doi.org/10.1093/eurheartj/ehw087 III Loop Recorders ILR Accuracy - Multicenter, Multidevice Comparison https://doi.org/10.1016/j.jacep.2025.12.039 IV Heart Failure Therapy when there is Cancer EMPATICC Trial https://doi.org/10.1093/eurheartj/ehaf705 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

A superb note on CPR and DNR orders, patients' vs doctors' preferences for statins, more on GLP-1s, another LAAC story, and some closing cautionary notes on PFA are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Addressing Inadequate Documentation of Unilateral DNR https://jamanetwork.com/journals/jama/fullarticle/2829203 Video: Can We Talk About CPR? https://www.youtube.com/watch?v=yTCRfY3ETvI Personal Reminiscences of CPR's Origin https://www.ajconline.org/article/S0002-9149(03)00977-9/pdf II Public Preferences for Statin Therapy Measuring Public Preferences for Statin Therapy https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844660 III GLP-1 RA News ACHIEVE Trial https://doi.org/10.1016/S0140-6736(26)00202-3 IV New Trial in GLP-1 for Patients with AF Seminal-AF Trial https://clinicaltrials.gov/study/NCT06499857 V Relationship between Spontaneous Echo Contrast and LAAC Outcomes OCEAN-LAAC Trial https://doi.org/10.1016/j.jacep.2025.09.028 News Release on Upcoming LAAOS-4 trial  https://www.phri.ca/watchman/ Reading the "Smoke" -- Editorial on OCEAN-LAAC https://www.jacc.org/doi/10.1016/j.jacep.2025.10.029 VI Concluding Remarks on My Talk at Western AF Delayed Myocardial Ischemia and Malignant Arrhythmias After PFA https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077983 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

This episode is a conversation with Dr. Jonathan Avery about why addiction has so much stigma and how that has stopped patients and families from getting real help.Most people still view addiction through a lens of shame and judgment, yet experts like Dr. Jonathan Avery are transforming how we understand and support those struggling. Dr. Avery is Vice Chair for Addiction Psychiatry and Professor of Clinical Psychiatry at Weill Cornell Medicine, known for pioneering efforts to reduce stigma and elevate evidence-based care. His work has transformed lives and inspired a new approach to addiction globally.He also founded the SAFE Program (Support, Advocacy, and Family Education) to provide evidence-based support to families affected by addiction. Dr. Kibby sits down with Dr. Avery to talk about how his personal experience with family addiction led him to develop groundbreaking programs and research to dismantle stigma, empower families, and open new pathways to recovery. In this episode, we break down:How addiction affects the brain and why stigma persists despite medical advancesThe innovative SAFE program supporting families affected by addictionDr. Avery's insights on challenging societal judgment and fostering compassionThe role of advocacy, policy, and personal understanding in changing the narrative around substance useHis upcoming book "Thriving with Addiction" and what it reveals about resilience and hope Whether you're supporting a loved one or seeking deep understanding, this episode is essential listening. This is your chance to hear from one of the most influential voices in addiction psychiatry who shares insights that could change the way you see and support those affected by addiction. Resources:Thriving with Addiction book and podcast with Dr. Jonathan Avery

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813 Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034 TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031 UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251 Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA II DNR in the Hospital Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203 GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193 TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 IV Good news in HFpEF Evidence ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016 V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Your brain isn't breaking. It's rewiring in ways no one explained, and for many women, menopause is the moment everything suddenly feels unfamiliar.Brain fog, sleep disruption, anxiety, memory lapses, and feeling unlike yourself can be deeply unsettling, especially when no one has given you a framework for what's happening. In this conversation, we explore the science behind midlife brain changes and why menopause is a neurological transition, not a personal failure.Dr. Lisa Mosconi is an associate professor of Neuroscience in Neurology and Radiology at Weill Cornell Medicine and director of the Alzheimer's Prevention Program and the Women's Brain Initiative. She is a world-renowned neuroscientist and the New York Times bestselling author of The Menopause Brain.In this episode, you'll discover • Why Alzheimer's risk begins in midlife, not old age • What estrogen actually does in the brain and why its shift matters • The hidden reason brain fog and mood changes show up during menopause • How the brain adapts and rebuilds after hormonal change • What science currently says about hormone therapy and brain healthMenopause can feel confusing and isolating, but understanding what your brain is doing can replace fear with clarity. Listen to learn how to navigate this transition with more confidence, compassion, and agency.You can find Lisa at: Website | Instagram | Episode TranscriptNext week, we're sharing a really meaningful conversation with psychiatrist and mental health educator Dr. Tracey Marks about what anxiety really is, why it feels so physical, and how understanding your brain can help you feel steadier and more at ease.Check out our offerings & partners: Join My New Writing Project: Awake at the WheelVisit Our Sponsor Page For Great Resources & Discount Codes Hosted on Acast. See acast.com/privacy for more information.

Ticagrelor vs prasugrel, a new LAAC device, pulsed field ablation AF results, lifestyle intervention in AF, the term "provider" vs "doctor," and coffee are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I TUXEDO-2 Trial TUXEDO-2 Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2844869 ISAR-REACT 5 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973 II VERITAS Study of Dual-Seal LAAO VERITAS Study https://doi.org/10.1016/j.jacep.2026.01.021 III PFA vs RF over 4 years Advent-LTO study https://www.nature.com/articles/s41591-026-04246-4 ADVENT Study https://www.nejm.org/doi/full/10.1056/NEJMoa2307291 SPHERE PER-AF Study https://www.nature.com/articles/s41591-024-03022-6 SINGLE SHOT CHAMPION Study https://www.nejm.org/doi/full/10.1056/NEJMoa2502280 BEAT PAROX-AF Trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829 IV What's in a Name — Use of the Term "Provider" Physicians Are Not Providers: The Ethical Significance of Names https://www.acpjournals.org/doi/10.7326/ANNALS-25-03852 V Coffee and Dementia Risk Coffee/Tea Intake and Dementia Risk https://jamanetwork.com/journals/jama/fullarticle/2844764 Mandrola Commentary: Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709 VI Lifestyle interventions Post AF ablation Improving Outcomes of AF by Lifestyle Interventions https://academic.oup.com/eurheartj/article/47/6/669/8243674 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Problems with the PREVENT score, a breakthrough in lipid-lowering therapy, a surprising benefit in stroke care, and more thoughts on statins and preventive care of heart disease are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I PREVENT Score PREVENT Equations in Young Adults https://doi.org/10.1016/j.jacc.2025.12.019 Hospital Readmission Reduction Program for HF https://pmc.ncbi.nlm.nih.gov/articles/PMC7664458/ II A New Breakthrough in LDL-C Management With an Oral PCSK9 Inhibitor https://www.medscape.com/viewarticle/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8 CORALreef Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002 CORALreef Outcomes Trial https://clinicaltrials.gov/study/NCT06008756 III A Win for the Factor XI Inhibitor Asundexian – OCEANIC Stroke Trial https://www.medscape.com/viewarticle/first-clear-win-factor-xia-inhibitors-stroke-reduced-2026a10003t0 OCEANIC-STROKE Slide deck https://clinicaltrialresults.org/wp-content/uploads/2026/02/26-02-02_ISC_OCEANIC-STROKE-primary.pdf OCEANIC-AF Study Stopped Early https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/ IV Statin Side Effects Assessment of AEs Attributed to Statins -- Meta-analysis https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext N-of-1 Trial to Assess AEs of Statins https://www.nejm.org/doi/full/10.1056/NEJMc2031173 When to Start a Statin Is a Decision About Preference -- Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808 V Heart Disease Statistics CV Statistics in the US, 2026 https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, huge news in the rapidly expanding world of PFA AF Ablation, obesity, and a beautiful trial studying an AI-enhanced diagnostic tool in the office are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Risk-Based TEE Omission in PVI 10.1016/j.hrthm.2025.04.056 External Link II PFA News BEAT PAROX-AF trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829 Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias Occurring After PFA https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.077983 Heart Rhythm TV: Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias  https://www.youtube.com/watch?v=M-npoLKmRa4 MAUDE Adverse Event report https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=23733351&pc=QZI III Obesity trends US State-Level Obesity Trends 1990-2022 and Forecasted to 2035 https://jamanetwork.com/journals/jama/fullarticle/2844495 IV New Tools in the Office TRICORDER Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02156-7/fulltext You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Lisa Mosconi is a world-renowned neuroscientist and the director of the Women's Brain Initiative at Weill Cornell Medicine, where she studies how sex differences and hormonal transitions influence brain aging and Alzheimer's disease risk. In this episode, Lisa explores why Alzheimer's disease disproportionately affects women and why longer lifespan alone does not explain their nearly twofold risk compared to men. She explains why Alzheimer's disease may be best understood as a midlife disease for women, beginning decades before symptoms appear, and how menopause represents a fundamental brain event that reshapes brain energy use, structure, and immune signaling. The conversation also examines what advanced brain imaging reveals about preclinical Alzheimer's disease, estrogen receptors in the brain, and why genetic risks such as APOE4 appear to affect women differently from men. Finally, Lisa discusses the nuanced evidence around menopause hormone therapy, the legacy of the WHI, her new CARE Initiative to cut women's Alzheimer's risk in half by 2050, and practical, evidence-based strategies to support brain health through midlife—including lifestyle, sleep, metabolism, mood, and emerging therapies such as GLP-1 agonists and SERMs (selective estrogen receptor modulators). We discuss: How Lisa's personal family history and scientific background led her to focus on the intersection of women's health, brain aging, and Alzheimer's disease (AD) [2:45]; The long preclinical phase of AD and the emotional burden carried by patients before dementia becomes severe [7:15]; How AD compares to other common forms of dementia: prevalence, pathology, symptoms, diagnostic challenges, and more [10:45]; Why AD disproportionately affects women: how AD is not simply a disease of old age or longevity but a midlife disease in which women develop pathology earlier [16:15]; Menopause as a leading explanation for women's increased Alzheimer's risk, and how advanced braining imaging can detect early changes in the brain [26:15]; How a new method for imaging estrogen receptors in the brain is changing how we think about the menopause transition [35:45]; What estrogen receptor imaging can and cannot tell us about hormone therapy's potential impact on brain health [48:45]; Lisa's studies on the relationship between levels of systemic estrogen and density of estrogen receptors in the brain [58:00]; Why blood estrogen levels poorly reflect brain estrogen signaling, and how tightly regulated brain hormone dynamics complicate our understanding of menstrual-cycle and lifestyle effects [1:02:15]; The CARE Initiative: Lisa's research program looking to slash AD rates in women [1:07:45]; The dramatic difference in AD risk between men and women associated with APOE4 [1:10:45]; What the evidence suggests about menopausal hormone therapy (MHT) and AD risk, and why timing, formulation, and uterine status appear to matter [1:12:00]; How the CARE initiative plans to study MHT and AD risk, within the practical constraints of a three-year research window [1:17:30]; How to think about starting hormone therapy during perimenopause: balancing symptom relief, hormonal variability, and individualized care [1:21:00]; Investigating selective estrogen receptor modulators (SERMs) as a targeted approach to brain health during and after menopause [1:25:00]; Why estrogen became wrongly associated with cancer risk and what the evidence actually shows [1:29:30]; Why better biomarkers are central to advancing women's Alzheimer's research [1:38:30]; Modifiable risk factors for dementia, the limitations of risk models, and questionable conclusions drawn from observational data [1:44:15]; GLP-1 agonists and brain health: exploring potential neuroprotective effects of GLP-1 agonists beyond metabolic benefits [1:49:00]; The importance of lifestyle factors in reducing risk of dementia: practical strategies for women to support brain health [1:53:45]; Why long-term, consistent lifestyle habits are essential for building cognitive resilience and protecting brain health over decades [2:01:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Ruth Gotian: Networking in the Age of AI Ruth Gotian is the former Chief Learning Officer and Associate Professor of Education in Anaesthesiology at Weill Cornell Medicine. Thinkers50 has ranked her the #1 emerging management thinker in the world, and she’s a top LinkedIn voice in mentoring. She’s the author of The Success Factor and, with Andy Lopata, The Financial Times Guide to Mentoring. Most of us recognize the value of building a better network, but we also know the time and dedication it takes. In this conversation, Ruth and I explore how we can use AI tools to do some of the administrative legwork so that we can spend more time on the real relationship-building. Key Points McKinsey reports that since the pandemic, most people's networks have shrunk or stalled. Consider the 90/9/1 rule: 90% of people lurk in online communities, 9% interact somewhat regularly, 1% post and lead the conversation. Use AI to enhance, not replace, your communications. Invite AI to do the administrative legwork (i.e. brainstorming, proofreading) so you focus on the human aspects. Ask AI to analyze speaker and attendee lists in advance at conferences in the context of your goals. Consider being the person that puts together an in-person dinner or gathering at a conference. Use AI to help you prep questions and discover the best people to invite. Ask AI to help complete your LinkedIn profile. An All-Star LinkedIn profile makes it substantially more likely that you'll get surfaced to others. Resources Mentioned Networking in the Age of AI by Ruth Gotian Related Episodes How to Grow Your Professional Network, with Tom Henschel* (episode 279) How to Build a Network While Still Doing Everything Else, with Ruth Gotian* (episode 591) The Key Elements of a Powerful Personal Brand, with Goldie Chan* (episode 757) Discover More Activate your free membership for full access to the entire library of interviews since 2011, searchable by topic. To accelerate your learning, uncover more inside Coaching for Leaders Plus.